The effect of IL2/IFN-α immunotherapy on actuarial survival (A), DFS (B), and relapse (C) in ML patients who received immunotherapy (n = 56) versus historical controls (n = 61, TRT + R) after autologous bone marrow transplantation (P < .01, P < .01, and P < .01, respectively).